NCT06026878

GNT Induction Treatment in Locally Advanced NPC

Name: Clinical Trial NCT06026878
Creator: Air Force Military Medical University, China
Keywords: Nasopharyngeal Carcinoma, gemcitabine,nimotuzumab, toripalimab, Phase 3, drug, clinical trial, China

Gemcitabine Combined With Nimotuzumab and Toripalimab as Induction Treatment Followed by Chemoradiotherapy for Locally Advanced Nasopharyngeal carcinoma-a Multicenter, Randomized Controlled Study

Air Force Military Medical University, China·Phase 3·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Nasopharyngeal Carcinoma
Drug/Device/Intervention: gemcitabine,nimotuzumab, toripalimab
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Air Force Military Medical University, China
Location: Xi'an, China

Timeline & enrollment

Phase: Phase 3
Start date: Sep 01, 2023
End date: Sep 30, 2027
Enrollment: 228 participants

Primary outcome

overall response rate

Summary

The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal carcinoma. It aims to answer whether gemcitabine, nimotuzumab and toripalimab as induction treatment show non-inferiority compared to GP induction chemotherapy. Participants will be randomly divided into two induction treatment groups.

ICD-10 classifications

Malignant neoplasm of nasopharynxMalignant neoplasm: Nasopharynx, unspecifiedMalignant neoplasm: Overlapping lesion of nasopharynxBenign neoplasm: NasopharynxMalignant neoplasm: Posterior wall of nasopharynx

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06026878
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06026878 through Pure Global AI's free database. This Phase 3 trial is sponsored by Air Force Military Medical University, China and is currently Recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 228 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.